Document is current
Any future updates will be listed below
-
Authors
Bult, L.
Braunstahl, G. J.
Aerts, J. G. J. V.
Bänffer, D.
van Campen, J. S. J. A.
van Daalen, M. S.
van Dooren, Y.
Flanders, U.
Geurts, E. S.
Hekking, P. P.
Heller - Baan, R.
Jans, M. J. A.
Kappen, J. H.
Mies, R. C. A.
Oppedijk, B.
de la Roij - Hartmans, M.
Van der Sar - Van der Brugge, S.
Türk, Y.
Vis, E.
Wolters, R.
Vasbinder, E. C.
Veen, J. C. C. M. in ‘t
-
Funding
Funding for this research was provided by:
Teva Pharmaceutical Industries
Transformation funds from health insurance companies
- License Information
-
More Information
Article History
Received: 11 July 2024
Accepted: 4 April 2025
First Online: 17 May 2025
Declarations
:
: Ethics approval for the EXACT@home study was provided by the Medical research Ethics Committees United (NL79996.100.22). Approval by the Institutional Research Board and Board of Directors of the Franciscus Gasthuis & Vlietland (FGV) hospital was also provided. The study is registered at clinicaltrials.gov (NCT05831566). Informed consent will be obtained from all subjects ().
: Not applicable.
: LB: Personal fees and/or speaker fees from Teva, Sanofi. GB: Grants and/or personal fees from AstraZeneca, Teva, Sanofi, GSK, ALK, Novartis, Glaxo Smith Kline, Sanofi, Chiesi. JA: none DB: none JC: Personal fees and/or speaker fees from Astra Zeneca, Sanofi Genzyme, Novartis, Chiesi, GSK MD: none YD: none UF: none EG: none PH: none RH: none MJ: none JK: Grants and/or personal fees from ALK, Chiesi, GSK, Novartis, AstraZeneca, Sanofi, Boerhinger, Teva, Viatris, Stallergen, Abbot, all outside the submitted work. RM: none BO: none MR: none SS: Personal fees and/or speaker fees from Genzyme, Chiesi, GSK, Boehringer Ingelhem, Astra Zeneca YT: none EV: Speaker fees from Boehringer Ingelheim, Sanofi, Astra Zeneca, Periscaldes, Springer Media BV, GSK RW: none ECV: Unconditional research grants from AstraZeneca and Pfizer JV: Unrestricted faculty research grants from GSK, Teva, AZ, Chiesi, Sanofi, and speaker fees from AZ, GSK, Sanofi, Chiesi, Stichting RoLeX and Health Investment.
